2024
Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis
Guru Murthy G, Ball S, Feld J, Abboud R, Haddadin M, Patel S, Kishtagari A, Hawkins H, Guerra V, Dworkin E, Tawfiq R, Dulak D, Feng A, Cotte C, Cohen-Nowak A, Shukla A, Balasubramanian S, Winer E, Foucar C, Abaza Y, Shallis R, Lin C, Badar T, Patel A, Im A, Szabo A, Atallah E. Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis. Blood 2024, 144: 3206-3206. DOI: 10.1182/blood-2024-211623.Peer-Reviewed Original ResearchHMA monotherapyTumor lysis syndromePhase 3 randomized clinical trialEvent free survivalHypomethylating agentsMulticenter retrospective analysisMyelodysplastic syndromeAdverse eventsUS academic medical centersClinical trialsUpfront settingFree survivalOverall survivalClinical outcomesRetrospective analysisClinical management of myelodysplastic syndromesIncidence of tumor lysis syndromeAcademic medical centerManagement of myelodysplastic syndromesAllogeneic stem cell transplantationSingle arm clinical trialResponse rateOutpatient settingStem cell transplantationMedical Center
2022
Contemporary Use of Hormonal Therapy in Endometrial Cancer: a Literature Review
Kailasam A, Langstraat C. Contemporary Use of Hormonal Therapy in Endometrial Cancer: a Literature Review. Current Treatment Options In Oncology 2022, 23: 1818-1828. PMID: 36417148, DOI: 10.1007/s11864-022-01031-6.Peer-Reviewed Original ResearchConceptsHormone receptor-positiveRecurrent endometrial cancerLow-grade diseaseHormone therapyEndometrial cancerReceptor-positiveSurgical candidatesTreatment optionsGonadotropin-releasing hormone agonistHormone treatmentLevonorgestrel intrauterine deviceSecond-line treatmentHormonal treatment optionsEstrogen receptor modulatorsAnti-estrogen treatmentEndometrial cancer treatmentLow performance statusStandard of careOral progesteroneUpfront settingMetastatic diseaseIntrauterine deviceProgesterone receptorPerformance statusHormone agonist
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply